Cancer nanotherapy suffers from low-yield delivery that is imposed by tumour pathophysiological barriers. Top-down drug delivery strategies, including exosomes and cell membrane-coated particles, can improve safety and efficacy owing to the innate biointerfacial properties of these platforms. Researchers at Universidade Nova de Lisboa discuss the technological challenges that need to be overcome for their clinical implementation.
Comparison of naturally secreted exosomes and engineered cell membrane-coated nanosystems
a, Main characteristics of natural exosomes and cell membrane-coated nanosystems. b, Comparative analysis of end-product and manufacturing properties of natural exosomes and cell membrane-coated nanosystems. aa, amino acids.